Navigation Links
Aurobindo Gets Tentative USFDA Approval For Its HIV-1 Drug

Aurobindo Pharma today said it has recieved a tentative New Drug Approval from USFDA for its fixed dose combination product used for treating HIV-1 infection//.

The new drug approval is for fixed dose combination drug product containing Lamivudine, Zidovudine, Nevirapine tablets used in the treatment of HIV-1 infection, the company informed the Bombay Stock Exchange.

The three drugs would now be available in one single tablet and the company is the sole manufacturer of this approved combination, it said, adding that this is the first NDA generic approval for a three-drug combination.

These three drugs have a market of 4.5 billion dollars worldwide and the usage of the drugs is growing due to the outstanding commitment of the US government in particular and the WHO to rehabilitate HIV patients, the company said adding, that with the approval its ARV product portfolio has increased to 15 including two NDA approvals.

Source:PTI News
'"/>




Page: 1

Related medicine news :

1. Aurobindo gets U.S. FDA approval for Cephalexin
2. US FDA approved Aurobindo Pharma to produce generic AIDS drug
3. Aurobindo Receives Approval from USFDA for anti-AIDS drug
4. Aurobindo Pharma Purchases US Manufacturing Facility
5. Aurobindo Gets USFDA Approval for Didanosine Chewable Tablets
6. Aurobindo Gets USFDA Approval for A 3-Drug Combination Pack
7. Tentative inhaled steroids is worse for lung patients
8. Cadila Gets Tentative USFDA Nod For Pravastatin Sodium Tablets
9. Lupin Gets Tentative Nod from FDA for Antidepressant Drug
10. Morepan to file new drug applications with the USFDA
11. Ranbaxy Gets USFDA Approval For Doxycycline Tablets

Post Your Comments:
(Date:11/29/2009)... , The Academy of General...of Orange county CA, received the Mastership Award...cognizes AGD members, commitment to excellence in ...completed 1,100 hours of approved continuing denta...cluding 400 hours dedicated to hands-on skills and...
(Date:11/29/2009)... Witnessing someone get blamed for something lead...nds , , SUNDAY, Nov. 29 (HealthDay News)...y reports, even when the target is innocent. , ...me someone else for a problem, even if it,s an unf... in blaming others, too. , "When we see others...
(Date:11/29/2009)... , Traditional healthcare... for viable affordable alternative care. Affordabl... (PRWEB) November 29, 2009 -- A... June of this year (2009) and has been met with en...and rapid success can be attributed to two things,...
(Date:11/28/2009)... Study finds gene variation believed to affect ci... (HealthDay News) -- New research suggests that an...be a factor in the development of bipolar disorder...xamination of the genetic makeup of 152 children w...tible to major mood swings, and 140 children witho...
(Date:11/27/2009)... , Biotech firm Replikins... of the H1N1 virus genomic data. It shows that th... of 3.7 (s.d. 4.5) during the virus,s current outb... levels this week of 2.0 (s.d. 0.1). The H1N1 infe... Boston (PRWEB) November 27, 20...
Breaking Medicine News(10 mins):Health News:Orange County Dentist Honored by The Academy of General Dentistry 2Health News:When Accusations Start to Fly, They Multiply 2Health News:Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities 2Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5
... Michael Moore,s healthcare,"horror" film SiCKO wi...and,politics with its Nov. 6 DVD release, which wi...use parties around the nation, the Registered Nurs...build on the,"Scrubs for SiCKO" campaign during th...
...November 5, 2007 Human Genome Sciences, Inc. (Nas...fe results from a Phase 2b clinical trial of the i...-2b), in combination with ribavirin in treatment-n...f work and less impairment of health-related quali...
... such fare more likely to act out at 7, 10, study ...-- Preschool boys exposed to violent television --...sive later in life, researchers warn. , Their find...he link does appear solid in the case of boys, sai...
...ou go to the hospital within one to two hours of t...es of getting proper treatment are nearly 70 perce...re seeking treatment, according to results present...immediately, by calling 911, gives them the best c...
...or the next two weeks,the "Help is Here Express" n... of Southern California, attempting to help uninsu... they need. The first stop will,be from 10 a.m. un...(PPA), a nationwide effort sponsored by America,s ...
...re/ - Halogen Software Inc., the leading,provider ...ement software,today announced the third quarter o...he organization set records in almost every catego...rganization and this new solution will enable us t...
Other Medicine News:Health News:Nurses Across Nation Host SiCKO House Parties to Urge Guaranteed Healthcare as DVD Released 2Health News:HGS unveils positive QOL results from Phase 2B trial of Albuferon for hepatits C 2Health News:HGS unveils positive QOL results from Phase 2B trial of Albuferon for hepatits C 3Health News:TV Violence May Spur Aggression in Boys 2Health News:TV Violence May Spur Aggression in Boys 3Health News:Mayo Clinic identifies new risk factor for heart attack patients 2Health News:'Help is Here Express' Bus Tour in California to Help Fire Victims Access Prescription Medicines 2Health News:'Help is Here Express' Bus Tour in California to Help Fire Victims Access Prescription Medicines 3Health News:Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue 2Health News:Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue 3
(Date:11/25/2009)...NCETON, N.J., Nov. 25 Ph...pharmaceutical company committed to discovering, d... viral infections, reported financial results for ...mber 30, 2009 Pharmasset held $58.4 million in cas..., Pipeline Update and 2009 Highlights ,, ...
(Date:11/25/2009)...EWATER, N.J., Nov. 25 The FDA gran...virine) tablets, a non-nucleoside reverse transcri...TI specifically indicated for use in treatment-exp...lure with HIV-1 strains resistant to an NNRTI and ...l approval is based on 48-week data from two Phase...
(Date:11/25/2009)...KING RIDGE, N.J., Nov. 25 Regado B...evelopment of antithrombotic aptamers with active ...EO and President, will be presenting at the Piper ...New York Palace Hotel in New York City. Dr. Mazzo...uesday, December 1 and will include an overview of...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Antibody targeting of glioblastoma shows promise in preclinical tests say Lombardi researchers 9441 1Antibody targeting of glioblastoma shows promise in preclinical tests say Lombardi researchers 9441 2Antibody targeting of glioblastoma shows promise in preclinical tests say Lombardi researchers 9441 3Global curbs on overfishing are beginning to work 9439 1Global curbs on overfishing are beginning to work 9439 2Opening a new window on daylight 9437 1Opening a new window on daylight 9437 2
..., , The Shortyavailable with both Impact and Impac...-face relationship with the scientific community g... pipetting easier and more effective., Shorter a...., Gets you closer to the working area for more...
...Impact2 Pipettors , , Available with five differe...pact2 pipettors can effectively meet the demands o...mic design and superior functionality as our multi...program for a wide range of liquid handling tasks ...
...est value in high performance electronic pipetting...ght design reduce hand fatigue and strain, Stres..., Color coding for easy volume identification, A...se Hamilton AdvanTip Low Retention and AdvanTip Pr...
BioPette E Electronic Pipettor, 100-1000l
Medicine Products: